Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration

Authors
Chiu Nan-ChangClifford, RobertHuang Li-MinHuang Yhu-CheringJo, Dae SunKim, Chun SooKim, Hwang MinKim, Kwang-NamKim, Kyung-HyoKim, Yun-KyungKlein, Nicola P.Ma, Sang-HyukPeltier, ChristopherSenders, ShellyShepard, JulieWu, Tsung ZuYeh, Shu JenZissman, EdwardGillard, PaulPovey, MichaelAbu-Elyazeed, RemonHenry, Ouzama
Issue Date
3-4월-2019
Publisher
TAYLOR & FRANCIS INC
Keywords
Measles-mumps-rubella vaccine; DTaP-IPV; varicella vaccine; immunogenicity; safety; co-administration
Citation
HUMAN VACCINES & IMMUNOTHERAPEUTICS, v.15, no.4, pp.786 - 799
Indexed
SCIE
SCOPUS
Journal Title
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume
15
Number
4
Start Page
786
End Page
799
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/66048
DOI
10.1080/21645515.2018.1554971
ISSN
2164-5515
Abstract
In many countries, a second dose of a combined measles, mumps, and rubella (MMR) vaccine is recommended at 4-6 years of age - similarly to the booster of diphtheria, tetanus, acellular pertussis, and inactivated polio vaccine (DTaP-IPV) and the second dose of varicella vaccine (VV). Vaccine co-administration is generally encouraged if no interferences exist among the vaccines. This phase IIIa, randomized, controlled trial (NCT01621802) evaluated the immunogenicity and safety of MMR-RIT (Priorix, GSK) when given as a second dose with or without co-administration of DTaP-IPV and VV, using MMR II (M-M-R II, Merck & Co Inc.) as comparator. Antibody geometric mean concentrations or titers (GMCs/GMTs) and response rates to the components of all the administered vaccines were assessed. Solicited, unsolicited, and serious adverse events were recorded. Four thousand eleven children aged 4-6 years were enrolled. MMR-RIT elicited immune responses that were not inferior to those of MMR II in terms of GMCs and seroresponse rates when administered alone or when co-administered with DTaP-IPV and VV. The immune responses to the co-administered vaccines in MMR-RIT recipients were non-inferior to those in MMR II recipients. MMR-RIT and MMR II demonstrated similar reactogenicity profiles; the most frequent solicited adverse events across vaccine groups and sub-cohorts were local pain and fever. In conclusion, the immunogenicity and safety profiles of MMR-RIT administered with or without DTaP-IPV and VV were similar to those of MMR II.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Yun Kyung photo

Kim, Yun Kyung
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE